Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.

Autor: Perry MWD; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Björhall K; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Bold P; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Brűlls M; Early Product Development & Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Börjesson U; Computational Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Carlsson J; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Chang HA; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Chen Y; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Eriksson A; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fihn BM; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fransson R; Advanced Drug Delivery, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fredlund L; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Ge H; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Huang H; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Karabelas K; Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lamm Bergström E; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lever S; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lindmark H; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Mogemark M; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Nikitidis A; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Palmgren AP; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Pemberton N; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Petersen J; Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Rodrigo Blomqvist M; Bioscience Cough and In Vivo, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Smith RW; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Thomas MJ; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Ullah V; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Tyrchan C; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Wennberg T; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Westin Eriksson A; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Yang W; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Zhao S; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Öster L; Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jun 24; Vol. 64 (12), pp. 8053-8075. Date of Electronic Publication: 2021 Jun 03.

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Autor: Skinner, M, Philp, K, Lengel, D, Coverley, L, Lamm Bergström, E, Glaves, P, Musgrove, H, Prior, H, Braddock, M, Huby, R, Curwen, J O, Duffy, P, Harmer, A R

Publikováno v: British Journal of Pharmacology; May2014, Vol. 171 Issue 9, p2308-2320, 13p, 1 Chart, 6 Graphs

The discovery of a selective and potent A2a agonist with extended lung retention.

Autor: Åstrand AB; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Lamm Bergström E; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Zhang H; Drug Safety & Metabolism, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Börjesson L; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Söderdahl T; Drug Safety & Metabolism, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Wingren C; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Jansson AH; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Smailagic A; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Johansson C; Drug Safety & Metabolism, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Bladh H; AstraZeneca R&D Lund SE-221 87, Lund, Sweden., Shamovsky I; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Tunek A; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden., Drmota T; RIA iMed, AstraZeneca R&D Mölndal SE-431 59, Mölndal, Sweden.

Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2015 Jun; Vol. 3 (3), pp. e00134. Date of Electronic Publication: 2015 May 04.

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19.

Autor: Pfeifer, Nathan D.¹ (AUTHOR) npfeifer@theravance.com, Lo, Arthur¹ (AUTHOR), Bourdet, David L.¹ (AUTHOR), Colley, Kenneth¹ (AUTHOR), Singh, Dave² (AUTHOR)

Publikováno v: CTS: Clinical & Translational Science. Nov2021, Vol. 14 Issue 6, p2556-2565. 10p.

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.

Autor: Matsukane, Ryosuke, Suetsugu, Kimitaka, Hirota, Takeshi, Ieiri, Ichiro

Publikováno v: Clinical Pharmacokinetics; Jul2022, Vol. 61 Issue 7, p955-972, 18p